Heart Failure Reviews最新文献_第2页

Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. 肥厚型心肌病的诊断和管理：欧洲与美国的指南。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-01 Epub Date: 2024-11-09 DOI: 10.1007/s10741-024-10464-0

Alberto Aimo, Giancarlo Todiere, Andrea Barison, Daniela Tomasoni, Giorgia Panichella, Ahmad Masri, Martin S Maron

{"title":"Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines.","authors":"Alberto Aimo, Giancarlo Todiere, Andrea Barison, Daniela Tomasoni, Giorgia Panichella, Ahmad Masri, Martin S Maron","doi":"10.1007/s10741-024-10464-0","DOIUrl":"10.1007/s10741-024-10464-0","url":null,"abstract":"Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting 1:200 to 1:500 individuals worldwide. Guidelines on the diagnosis and management of HCM have been recently published by the European Society of Cardiology (ESC) and American societies. The ESC guidelines cover a broad range of cardiomyopathies, including HCM, with 119 recommendations, whereas the American guidelines focus exclusively on HCM with 141 specific recommendations. Both guidelines emphasize a comprehensive diagnostic approach, including imaging and genetic testing, but differ in some specific aspects. For example, sudden cardiac death (SCD) risk assessment is a primary point of divergence. The ESC guidelines advocate for the use of a validated Risk-SCD calculator, while the American guidelines rely on specific risk markers for individualized risk evaluation. Management strategies also vary: both guidelines prioritize beta-blockers and calcium channel blockers in patients with resting or provocable left ventricular outflow tract (LVOT) obstruction. If beta-blockers (or verapamil/diltiazem) are ineffective, either disopyramide or the myosin inhibitor mavacamten may be an option with slightly different indications among the two guidelines. Septal reduction therapy is recommended in ESC guidelines for symptomatic patients with significant LVOT gradients, while American guidelines suggest earlier myectomy for certain clinical factors and emphasize shared decision-making. The ESC guidelines recommend sequential atrioventricular pacing and dual-chamber defibrillators for reducing LVOT gradients. The American guidelines focus on genetic testing for risk assessment and suggest periodic cardiac magnetic resonance imaging. This paper provides a detailed comparison of these guidelines, highlighting key differences and areas needing further research and expert debate.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"315-325"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maternal heart failure: state-of-the-art review. 产妇心力衰竭：最新综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-01 Epub Date: 2024-11-12 DOI: 10.1007/s10741-024-10466-y

Usman S Najam, Jitae A Kim, Sophie Y Kim, Gurleen Wander, Mario Rodriguez, Hafeez Ul Hassan Virk, Mark R Johnson, W H Wilson Tang, Chayakrit Krittanawong

{"title":"Maternal heart failure: state-of-the-art review.","authors":"Usman S Najam, Jitae A Kim, Sophie Y Kim, Gurleen Wander, Mario Rodriguez, Hafeez Ul Hassan Virk, Mark R Johnson, W H Wilson Tang, Chayakrit Krittanawong","doi":"10.1007/s10741-024-10466-y","DOIUrl":"10.1007/s10741-024-10466-y","url":null,"abstract":"Pregnancy is a period of substantial changes to the body's normal physiology, and the failure to adapt to these changes can lead to life-threatening pathology, particularly involving the cardiovascular system. In comparison to pre-pregnancy physiology, pregnant women have increased blood volume and physical demands which exert increased stress on the heart. This is important to consider in women with and without previously diagnosed cardiovascular disease, as the physiologic changes during pregnancy and postpartum can lead to sudden decompensation. The management of heart failure is particularly important as it remains the most common cardiovascular complication during pregnancy and is associated with substantial maternal and fetal morbidity and mortality. This is especially true in patients with pre-existing heart failure, who should receive counseling before conception and in certain cases be advised against pregnancy. For these reasons, healthcare professionals must be well-versed in the different strategies of diagnosis, management, treatment, and monitoring. This review will outline the pathophysiology, diagnostics, management, and general approach to heart failure in pregnant patients.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"337-351"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diuretic strategies in acute decompensated heart failure. 急性失代偿性心力衰竭的利尿策略。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-01 Epub Date: 2024-12-15 DOI: 10.1007/s10741-024-10473-z

Kevin Bryan Lo, Anju Nohria

引用次数: 0

Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations). Sacubitril/缬沙坦在广泛的心力衰竭患者中的作用（从作用机制到特定人群的结果）。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-01 Epub Date: 2025-01-07 DOI: 10.1007/s10741-024-10471-1

Przemyslaw Rajzer, Jan Biegus

{"title":"Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).","authors":"Przemyslaw Rajzer, Jan Biegus","doi":"10.1007/s10741-024-10471-1","DOIUrl":"10.1007/s10741-024-10471-1","url":null,"abstract":"Heart failure (HF) represents a significant global health challenge, characterized by high morbidity and mortality rates, decreased quality of life and a significant financial and economic burden. The prevalence of HF continues to rise, driven by an ageing population and an increasing burden of comorbidities such as hypertension, diabetes and obesity. Understanding the complex pathophysiology and developing effective treatments are critical for improving patient outcomes, yet the range of effective, life-prolonging medication classes has remained mostly constant in the last few decades. The introduction of angiotensin receptor neprilysin inhibitors (ARNI) was a major breakthrough in HF management, for the first time targeting the natriuretic peptide system in addition to the renin-angiotensin-aldosterone pathway to potentiate the effects of older drug classes. ARNI shows superiority in clinical outcomes compared to previous guideline-directed therapies, especially in patients with reduced ejection fraction (EF). It has now been implemented into international guidelines, endorsing its use in patients with HF and reduced ejection fraction (HFrEF) and HF with mildly reduced ejection fraction (HFmrEF). This review summarises the mechanism of action of Sac/Val, presents key clinical trials in a range of patient populations and HF aetiologies and outlines gaps in knowledge and potential novel uses of Sac/Val.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"387-405"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning in predicting heart failure survival: a review of current models and future prospects. 机器学习预测心力衰竭生存：当前模型的回顾和未来展望。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-01 Epub Date: 2024-12-10 DOI: 10.1007/s10741-024-10474-y

Emmanuel Kokori, Ravi Patel, Gbolahan Olatunji, Bonaventure Michael Ukoaka, Israel Charles Abraham, Victor Oluwatomiwa Ajekiigbe, Julia Mimi Kwape, Adetola Emmanuel Babalola, Ntishor Gabriel Udam, Nicholas Aderinto

{"title":"Machine learning in predicting heart failure survival: a review of current models and future prospects.","authors":"Emmanuel Kokori, Ravi Patel, Gbolahan Olatunji, Bonaventure Michael Ukoaka, Israel Charles Abraham, Victor Oluwatomiwa Ajekiigbe, Julia Mimi Kwape, Adetola Emmanuel Babalola, Ntishor Gabriel Udam, Nicholas Aderinto","doi":"10.1007/s10741-024-10474-y","DOIUrl":"10.1007/s10741-024-10474-y","url":null,"abstract":"Heart failure is a complex and prevalent condition with significant implications for patient management and survival prediction. Traditional predictive models often fall short in accuracy due to their reliance on pre-specified predictors and assumptions of variable independence. This review aims to assess the role of machine learning (ML) algorithms in predicting heart failure survival, comparing their performance with traditional statistical methods and identifying key predictive features. We conducted a review of studies utilizing ML algorithms for heart failure survival prediction. Data were sourced from PubMed/MEDLINE, Google Scholar, ScienceDirect, Embase, DOAJ, and the Cochrane Library, covering studies published until July 2024. A total of 10 studies were reviewed, encompassing 468,171 patients with heart failure. ML algorithms, particularly random forests and gradient boosting methods, demonstrated superior performance compared to traditional statistical models. These algorithms effectively identified key risk factors and stratified patients into risk categories with high accuracy. Notably, extreme learning machine (ELM) and CatBoost models showed exceptional predictive capabilities, as indicated by metrics such as Harrell's concordance index (C-index) and area under the curve (AUC). Key predictive features included ejection fraction (EF), serum creatinine (S Cr), and blood urea nitrogen (BUN). ML algorithms offer significant advantages in predicting heart failure survival by uncovering complex patterns and improving risk stratification. Their integration into clinical practice could lead to more personalized treatment strategies and enhanced patient outcomes. However, challenges such as data quality, model interpretability, and integration into clinical workflows need to be addressed.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"431-442"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review. 心肌肌球蛋白抑制剂治疗肥厚性心肌病的临床应用：范围综述。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-01 Epub Date: 2024-12-17 DOI: 10.1007/s10741-024-10476-w

Leen Othman, Lida Koskina, Nicholas Huerta, Shiavax J Rao

{"title":"The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review.","authors":"Leen Othman, Lida Koskina, Nicholas Huerta, Shiavax J Rao","doi":"10.1007/s10741-024-10476-w","DOIUrl":"10.1007/s10741-024-10476-w","url":null,"abstract":"Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular, non-dilated hypertrophy in the absence of another secondary underlying cause. There has been an ongoing increase in the diagnosis of HCM over the past couple of decades, prompting further work in the area of pharmacological and interventional therapies. This scoping review aimed to summarize the traditional therapeutic options for HCM and to explore emerging research on novel cardiac myosin inhibitors (CMIs) as a new option for pharmacologic management of HCM. A PRISMA search strategy was carried out to identify the pertinent literature on mavacamten and aficamten-two novel CMIs. Seventeen studies were included. Based on the results of the studies included in this review, cardiac myosin inhibitors have been proven to be a safe and efficacious second-line option for the management of HCM. In the foreseeable future, based on results of ongoing studies investigating patient outcomes and side-effect profile, CMIs may potentially play a larger role as part of standard treatment of HCM.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"453-467"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-02-25 DOI: 10.1007/s10741-025-10498-y

Veraprapas Kittipibul, Andrew P Ambrosy, Stephen J Greene

引用次数: 0

Worsening heart failure: progress, pitfalls, and perspectives.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-02-20 DOI: 10.1007/s10741-025-10497-z

Fonseca Cândida, Baptista Rui, Franco Fátima, Moura Brenda, Pimenta Joana, Pedro Moraes Sarmento, Silva Cardoso José, Brito Dulce

引用次数: 0

The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.